Bevirimat (PA-457)

HOME

HIV and AIDS

Hepatitis B

Hepatitis C

HIV-HCV Coinfection

HIV-HBV Coinfection

HIV and AIDS Articles
FDA-approved Treatments Experimental Treatments Top New Articles Guidelines

Bevirimat (PA-457)

What is Bevirimat?
• Bevirimat is an experimental anti-HIV drug being developed by Panacos Pharmaceuticals. It is currently in Phase II clinical trials.

Panacos Announces Data from Phase 2b Trial of HIV Maturation Inhibitor Bevirimat (PA-457) - 3/07/08

New Maturation Inhibitor May Be More Potent than Bevirimat (PA-457) - 8/24/07

Maturation Inhibitor Bevirimat (PA-457) Demonstrates Good Anti-HIV Activity in Phase 2b Study - 6/22/07

Panacos Announces Disappointing Results for Bevirimat 1/12/07

Safety and Antiviral Activity of PA-457, the First-in-class Maturation Inhibitor: A 10-Day Monotherapy Study - 1/13//06

Protease Inhibitors

Agenerase (amprenavir)

Aptivus (tipranavir)

Crixivan (indinavir)

Invirase (saquinavir hard gel)

Kaletra (lopinavir/ritonavir)

Lexiva (fosamprenavir)

Norvir (ritonavir)

Prezista (darunavir)

Reyataz (atazanavir)

Viracept (nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir (zidovudine/lamivudine)

Epivir (lamivudine; 3TC)

Emtriva (emtricitabine; FTC)

Epzicom (abacavir + lamivudine)

Retrovir (zidovudine; AZT)

Trizivir (abacavir + zidovudine +lamivudine)

Truvada��(tenofovir / emtricitabine)

Videx (didanosine; ddI)

Viread (tenofovir)

Zerit (stavudine; d4T)

Ziagen (abacavir)

non Nucleoside Reverse
Transcriptase Inhibitors

Etravirine (Intelence; TMC125)

Rescriptor (delavirdine)

Sustiva (efavirenz)

Viramune (nevirapine)

Entry Inhibitors
(including Fusion Inhibitors)

Fuzeon (enfuvirtide, T-20)

Selzentry ( maraviroc)

Fixed-dose Combinations

Atripla (efavirenz + emtricitabine + tenofovir)

Combivir (zidovudine + lamivudine)

Trizivir (abacavir + zidovudine + lamivudine)

Truvada (tenofovir + emtricitabine)

Integrase Inhibitor

Isentress (raltegravir)